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Chapter 7: Discussion and summary
Manganese neurotoxicity: a model for oxidative
stress and selective neurodegeneration
in the basal ganglia
Intoxications and other pathologies of the CNS are most often
characterized by selective damage. In particular, the basal ganglia that control
automatic movements are vulnerable brain regions under abnormal conditions
such as idiopathic Parkinson's disease (iPD) and m€rng€rnese (Mn) poisoning.
At present the etiologr and pathogenesis of iPD (and related disorders) as well
as the mechanism of Mn-induced neurodegeneration of the basal ganglia (or
most other intoxications affecting this area) are unkown. In addition, both
pathologies result in irreversible hypokinesia (rigidity, tremor, bradykinesia,
unstable postural reflexes, dystonia), while there is no long-lasting effectlve
treatment available.
Specific properties, or a unique combination of basic, endogenous factors
of the basal ganglia, such as the presence of dopamine (DA), glutamate (Glu),
iron (Fe) and neuromelanin, may render them more susceptible to damage, in
particularly oxidative injury, than other brain regions. Since all these intrinsic
factors can participate in oxidative stress events via different mechanisms (see
Chapter I ), which are often considered a final common pathway of cell death,
this may explain the selective vulnerability of the basal ganglia under
abnormal conditions. On the other hand, defects in generally occurring cell
systems, including the mitochondrial respiration chain (the main natural
source of reactive oxygen species) and oxidative defense mechanisms such as
glutathione (GSH) metabolism, may lead to selective oxidative damage of the
basal ganglia because of their intrinsic metabolic properties. Questions
addressed to understand this vulnerability may provide better fundamental
and therapeutic insight for the treatment of basal ganglia disorders.
One should bear in mind that there exists no 'perfect' animal model for
PD as it occurs in humans. All models of Parkinsonism show differences and
similarities with iPD, of which Mn intodcation may be specified as a model for
dystonia. Table I summarizes various oxidative stress phenomena in relation
to basal ganglia lesions which cause hypokinetic movements as outlined in
Chapter 1, including Mn-induced lesions which are described in this thesis. In
the present thesis, Mn-neurotoxicity has been chosen as a model to study in
uiuo fundamental aspects of oddative stress and selective neurodegeneration
in the rat basal ganglia. In particular, the role of iron and DA in producing
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oddative stress by Mn is emphasized as a relevant and integral part of Mn
neurotoxicity and one of the main topics in current PD research.
Using systemic Mn administration to study its neurotoxicity has the
practical disadvantage, that Mn accumulates (very) slowly in the brain and that
the onset of lesions in the basal ganglia will not occur until several months
after chronic exposure. Since some authors have reported acute depletions of
DA after a single Mn injection into rat striatum or substantia nigra, we used
this experimental approach to further characterize an acute Mn intoxication
model in teh rat. It followed from our studies that intrastriatal Mn injection
produced time- and dose-dependent DA depletions and displayed selective
nerve cell death as reflected in nsCa accumulation in the basal ganglia, which
virtually matched the described pathologl after chronic systemic exposure to
Mn. The observed regional distribution of asCa accumulation in striatum,
globus pallidus (GP), entopeduncular nucleus (external GP), substantia nigra
and several thalamic nuclei involved in motor functions, suggested both pre-
and post-slmaptic damage to the DAergic nigrostriata-l pathway. Postslmaptic
damage probably includes GAElAergic neurons.
Selective effects of Mn were also observed at the level of biogenic amines
in striatum and substantia nigra: partially reversible DA depletions, and
reversible changes of noradrenaline (NE) and serotonin neurotransmitter levels
in striatum. In addition, DA neurotransmission in striatum, based on
measurements of the'synaptic' DA-metabolite 3-methoxytyramine, was
completely abolished at day I and 3 after Mn injection, but recovered within
6 weeks. This indicated a functional restoration of DA neurotransmission,
despite still substantial losses of tissue DA, and its metabolites 3,4-
dihydro>qlphenylacetic acid (DOPAC) and homovanillic acid (m/A).
Selectivity of both Mn and Fe was further tested by comparing injections
of either metal in striatum or hippocampus, two areas with a respectively high
and low DA and iron content. These studies demonstrated a relatively low
toxicity of Mn in the hippocampus, and a high toxicity of Fe in the brain
independent of the injection site. The finding that the S/rus dentatus, a
subregion of the hippocampus with the highest iron levels locally (albeit still
low compared to the basal ganglia), was the preferential site for 'sCa
accumulation after intrahippocampal Mn-injection, was consistent with our
hypothesis that Mn needs iron or iron-binding sites to exert its toxicity. In
addition, the selective lesions by Mn and extensive damage by Fe after
intracerebral injection suggest different mechanisms of action.
Characterized in more detail, this Mn model offered the possibility to
further study the mechanism or prevention of Mn neurotoxicity with the use
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of pha,rmaceutical intervention (antioxidants, DA/Glu (ant)agonists, etc.). With
this in mind, the distribution, retention and transport of Mn was studied,
which could possibly help to explain some aspects of its selective toxicity.
Using trace injections of 5aMn into striatum or substantia nigra, it was not only
demonstrated that substantial amounts of label were retained in both regions
until at least 2-3 days after injection, but also that Mn was transported by
neurons. By blocking axonal transport through the medial forebrain bundle
using a local colchicine injection or mechanical transection of the bundle, or
by producing selective lesions of the DAergic nigrostriatal pathway (using 6-
OHDA) or GABAergic striatonigral pathway (using quinolinic acid), it was
shown that Mn is transported through nigro-striatal and striato-nigral nerve
fibres in anterograde direction.
In addition, the striatum lesioned with quinolinic acid, which is depleted
of most intrinsic nerve cells and contains reactive glial cells, accumulated three
times more s'Mn, suggesting a predominant micro- and/or astroglial
localization of saMn. The exact cellular entity responsible for Mn transport is
not known from these or other studies, but it is discussed that iron transport
pathways and storage proteins are the most likely candidates that may
determine selective transport and accumulation of Mn in and within the basal
ganglia.
Since it has been hypothesized from in uitro studies, that Mn may
produce free oxygen radicals directly or indirectly via auto-oxidation of
catecholamines, our next goal was to measure free o>grgen radicals in uiuo in
direct relation to (biochemical) damage. Recently, salicylate (SA) has been used
as an in uiuo trapping agent for the highly deleterious hydroxyl radicals ( OH),
which upon reaction with SA form the relatively stable adducts 2,3- and 2,5-
dihydro>rybenzoic acids (DHBA). For that purpose, we developed a HPLC
method to analyze catechol- and indoleamines and related metabolites in
combination with SA and its hydroxylated adducts 2,3- and 2,S-DHBA (in
striatum and CSF). This enabled us to study metal-induced OH formation and
DA/5-HT changes simultaneously in the same tissue samples. Since iron is
considered to catalyze the Haber-Weiss reaction in ui.uo, thereby producing OH,
it was obvious to study brain Fe intodcation using this OH-trapping
technique. In addition, the contrast between a hlpothesized different
mechanism of action of both transition metals (as concluded above), and their
close physico-chemical interrelationship and thus possible interference of Mn
with brain iron homeostasis, may shed light on aspects of Mn neurotodcity
and oddative stress. In other words, endogenous iron released by Mn may be
the crucial factor in Mn-todcitv.
r 8 l
Time-course studies expandlng from 3O minutes to I month following
intrastriatal Fe injection revealed that 2,S-DHBA, the non-enz5rmatic product
from SA and OH, peaked at 3O minutes (1O-fold increase), whereas DA and 5-
HT levels were relatively unaltered during the first two hours. These data
suggest, that Fe-triggered OH formation precedes striatal DA (which was
irreversibly depleted) and 5-HT depletions which occurred at later time points
(beyond 2 hours). In addition, OH are continuously formed during Fe-induced
neurodegeneration in a gradually declining fashion. At two hours after Fe
injection, the high DOPAC level, no change in FIVA, and a moderately reduced
DA level, indicated specific enhancement of both DA anabolism and
catabolism. Based on the iron dependency of the rate-limiting DA-slmthetic
en4/rne tlrosine hydro>rylase (TH), and the specific localization of TH (cytosol)
and the DA catabolic enzymes monoamine oxidase (outer membrane of
mitochondria) and catechol-o-methyltransferase (extraneuronally), it was
concluded that this Fe-effect was within the DA neuron.
Whether the SA OH-trapping technique could be applied in the clinic to
study chronic conditions of oxidative stress, for example by measuring SA
adducts in CSF of PD or amyotrophic lateral sclerosis (ALS) patients, was
experimentally investigated in CSF of rats injected with Fe into striatum.
Indeed, DHBA levels in CSF of these rats were significantly elevated at time-
points 30 minutes and 3 days. However, less severe "lesions" produced by Mn
in striatum (as examined until l8 h; see Chapter 6) did not induce significantly
elevated DHBAlevels in CSF. Whether chronic neurodegenerative diseases may
produce increased DHBA levels in CSF remains to be resolved. Since
comparable doses of SA (lOO mg/kg) are used to treat juvenile arthritis, the
relatively high SA dose needed for such studies in humans is still in the
clinically safe range.
Subsequent studies described in Chapter 6 showed that intrastriatal Mn
injections increase 2,3-DHBA formation in a time- and dose-dependent manner
in striatum, suggesting that Mn induces OH in uiuo. Since the 2,3-DHBA
effects by Mn demonstrated a time-delayed increase (maximum at 6-18 h), in
contrast to our 2,3-DHBA effect by Fe over time, it was concluded that Mn
induces OH by an indirect mechanism, implicating that Mn can not catalyze
the Haber-Weiss reaction in utuo.It also followed from time- and dose-related
effects (of simultaneously measured DA and 2,3-DHBA) that DA depletion and
OH formation by Mn appear to be independent processes. It has been
suggested by in uitro observations that Mn oxidizes DA rapidly and irreversibly
to its cyclized o-DA-quinone resulting in a decrease of DA, but not in the
formation of reactive oxygen species, since o>rygen is neither consumed nor
required. This is in line with the rapid initial DA-depleting effect induced by Mn
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in uiuo without a significant rise of OH in the flrst two hours, indicating that
Mn-induced DA depletion in uiuo is similar to that observed in vitro. However,
the reducing capacity of DA neurons will probably be exhausted by such DA
(auto)oxidation processes (and together with mitochondrial ener$/ depletion)
resulting in, for example, a severely compromised GSH metabolism as has
been shown by Liccione and Maines, which could make these cells potentially
more susceptible (e.g. to excitotoxicity).
In an attempt to find out via what mechanism OH are formed by Mn we
investigated the possible role of DA (or non-enzymatic DA (auto)oddation
products) and 'free' or low-molecular-weight (Ln/fW iron as a potenttal source
that can catalyze the Haber-Weiss reaction. Studies in which rats were
depleted of striatal DA (9oo/o reduction) by pre-treatment with reserpine, or in
which rats received co-injections of Mn and the iron chelator deferoxamine
{DFX) into striatum, did not demonstrate attenuation of Mn-induced 2,3-DHBA
formation, while the extent of DA reductions was similar. Furthermore, the
level of chelatable LMW iron in Mn-injected striata was not different from
controls. In conclusion, these findings suggest that neither DA or DA
(auto)oxidation products nor chelatable iron participate in Mn-induced OH
formation.
Other possibilities by which the observed Mn-induced OH formation
might be explained are ( 1) through the formation of pero>rlmitrite (ONOOH), the
reaction product of NO and Or-, or (2) heme-associated ferryl radicals. The
former implicates iron-independent OH formation from the decomposition of
pero44itrite. Since Mn shares aspects of (additional) excitotoxicitywith several
other mitochondrial toxins whose neurotoxicity could be attenuated by NO-
slmthase inhibitors, NO-triggered oxidative damage after Mn might be a
possible mechanism. Other features of Mn toxicity, such as impairment of
(mitochondrial) GSH metabolism and several mitochondrial energr supply
functions by Mn, including heme-associated functions (respiratory and P-450
cytochromes) and oxidative phosphorylation, may lead to or be the result of
formation of heme-associated ferryl radicals, which are similar in reactivity to
OH or ferryl iron (FeO2-). If the postulated formation of heme-associated ferryl
radicals (and HrOr) occurs, this would imply that such radicals are capable of
hydroxylating SA, which is not unlikely and could be tested in uttro.
In summary, it is proposed that the selective neurotoxicity of Mn within
the basal ganglia is most likely exerted via iron-dependent distribution
characteristics (transferrin receptors, ferritin) and subsequent transport (Ca
uniporter) that determine the preferential accumulation into mitochondria.
Here, high local Mn concentrations will disturb several important energ/
supply functions and anti-oxidant defense mechanisms (GSH), resulting in
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local oxidative stress possibly through formation of site-specific heme-
associated ferryl radicals, pero>qmitrite, and/or pero>+mitrite-derived OH,
which eventually will lead to cell death. In this respect, a study of the role of
DA oddation products (quinones) might be of value to assess the reducing
capacity of the neuron.
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Table l: Oxidattue stress phenomena in relation to idtopathic Parktnson's disease and three representatiue models oJ
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aberrant metabolism Gp2a, shift Fell*III2326. protection by iron compacta: dopamine and ferritin3a3s, attenuation
ferritin25 J and 1'u, chelation3o, binding to glial cells33, transferrin by iron chelatlon36
transf'errin receptor trarsferrin and ferritin3r, receptor density J in Sf '
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iron in Lewy bodies2s and via lron pathways32
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Dopamine autoxidation 5-S-cysteinyl- In Ditro DA-quinones & No role of dopamineao In u,tro autoddation of 6-
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antagonistsar antagonistsar antagonistsa'
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stimulatess2, MPTP and in uiuo56'57
inhibitss2 53
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